1. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce.JAMA. 2003;290:2443–2454.
2. Food and Drug Administration [webpage on the Internet]. Public Health Advisory: Safety warnings regarding use of fentanyl transdermal skin patches [updated 15 July 2005; cited 1 March 2008]. Available from: http://www.fda.gov/cder/drug/advisory/fentanyl.htm
3. Health Canada [webpage on the Internet]. Important Safety Information: DuragesicŖ fentanyl transdermal system [updated 13 September 2005; cited 1 March 2008]. Health Canada. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/duragesic_hpc-cps_e.html
4. Food and drug Administration [webpage on the Internet]. Information for Healthcare Professionals: Fentanyl Transdermal System (marketed as Duragesic and generics) [updated 21 December 2007; cited 24 Feb 2008]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/fentanyl_2007HCP.htm
5. Stanly TH. The history and development of the fentanyl series.J Pain Symptom Manage. 1992;7:S3-S7.